Healthcare >> Analyst Interviews >> October 12, 2001
KARL KEEGAN graduated from University College Dublin with first-class
honours degree (BSc) in pharmacology. He received a Parke-Davis Warner-
Lambert scholarship to Cambridge where he attended Jesus College. Dr.
Keegan specialised in biophysics, particularly the electrophysiology of
neuropeptides in brain slices. He received an MPhil and PhD for this
work. In 1992, he completed postdoctoral training at the Department of
Neurophysiology, Division of Neuroscience, Baylor College of Medicine,
Texas, funded by a National Institutes of Health scholarship and an
Epilepsy Society young investigator award. In 1993, he returned to the
UK to take up a research position with the Department of Biophysical
Sciences at SmithKline Beecham Pharmaceuticals. While at SB, Dr. Keegan
moved into a commercial and strategic role within the Strategic Product
Development group, where he was responsible for marketing of the early-
stage neuroscience portfolio and commercial evaluation of potential in-
licensing candidates. In 1997, he joined Dresdner Kleinwort Benson as a
Biotechnology Analyst, before moving to UBS Warburg in 1999. Dr. Keegan
currently heads the European Biotechnology research team in London. Profile
companies?
Dr. Keegan: The coverage is everything outside of big pharma. That
includes life sciences companies,
